Modulatory mechanisms of TARP γ8-selective AMPA receptor therapeutics
- Nat Commun. 2023 Mar 25;14(1):1659. doi: 10.1038/s41467-023-37259-5.
- 1. Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK.
- 2. IST Austria, Klosterneuburg, Austria.
- 3. Department of Molecular Physiology and Biophysics, Vanderbilt University, School of Medicine, Nashville, USA.
- 4. Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK. [email protected].
- # Contributed equally.
AMPA glutamate receptors (AMPARs) mediate excitatory neurotransmission throughout the brain. Their signalling is uniquely diversified by brain region-specific auxiliary subunits, providing an opportunity for the development of selective therapeutics. AMPARs associated with TARP γ8 are enriched in the hippocampus, and are targets of emerging anti-epileptic drugs. To understand their therapeutic activity, we determined cryo-EM structures of the GluA1/2-γ8 receptor associated with three potent, chemically diverse ligands. We find that despite sharing a lipid-exposed and water-accessible binding pocket, drug action is differentially affected by binding-site mutants. Together with patch-clamp recordings and MD simulations we also demonstrate that ligand-triggered reorganisation of the AMPAR-TARP interface contributes to modulation. Unexpectedly, one ligand (JNJ-61432059) acts bifunctionally, negatively affecting GluA1 but exerting positive modulatory action on GluA2-containing AMPARs, in a TARP stoichiometry-dependent manner. These results further illuminate the action of TARPs, demonstrate the sensitive balance between positive and negative modulatory action, and provide a mechanistic platform for development of both positive and negative selective AMPAR modulators.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: iGluRResearch Areas: Neurological Disease
-
target: iGluRResearch Areas: Neurological Disease